Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Metabolism and nutrition disorders – page 9

  • 755 clinical trials
  • 276 recruiting
  • 239 conditions
  • 26 countries

Conditions in this area

239 conditions with trials, the busiest first

Obesity122Type 2 diabetes mellitus85Overweight58Type 1 diabetes mellitus41Endocrine ophthalmopathy26Metabolic dysfunction-associated steatohepatitis24Diabetes mellitus21Non-alcoholic steatohepatitis17Type IIa hyperlipidaemia15Glycogen storage disease type II14Hypercholesterolaemia14Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Alpha-1 antitrypsin deficiency11Chronic kidney disease10Fabry's disease10Osteoporosis10Hypertriglyceridaemia9Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Dyslipidaemia8Iron deficiency8+215

Clinical trials in Metabolism and nutrition disorders

755 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

755 clinical trials

Diabetes mellitus+1

Recruiting

A study of estradiol and progesterone treatment for blood sugar control in women with type 1 or type 2 diabetes during or after menopause

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Estradiol
  • Sponsor:Amsterdam UMC Stichting

MELAS syndrome+2

Recruiting

A study testing sonlicromanol in adults with genetically confirmed mitochondrial DNA 3243A>G variant causing mitochondrial disease

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Sponsor:Khondrion B.V.

Iron deficiency+1

Recruiting

A Study of Ferric Carboxymaltose to Improve Exercise Ability in Patients with Pulmonary Hypertension and Iron Deficiency

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Ziekenhuis Oost Limburg

Coronary artery disease+1

Recruiting

Study of dapagliflozin and semaglutide to reverse prediabetes to normal blood sugar levels in patients with coronary artery disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Region Midtjylland

Hypophosphatasia

Recruiting

A Study Testing the Safety and Tolerability of ALE1 in Healthy Adults and Adults with Hypophosphatasia

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:ALE1
  • Sponsor:Alesta Therapeutics B.V.

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Teplizumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Leukodystrophy

Recruiting

A study of guanabenz acetate for children with vanishing white matter disease who started treatment in early childhood

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Guanabenz Acetate
  • Sponsor:Amsterdam UMC Stichting

Phenylketonuria

Recruiting

A Study of Repinatrabit Compared to Placebo for Treatment of Patients with Phenylketonuria

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Congenital leptin deficiency

Recruiting

A Study of Mibavademab for Weight Loss in Children, Adolescents and Adults with Obesity Caused by LEP Gene Mutations

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mibavademab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hypochondroplasia

Recruiting

Long-Term Study of Vosoritide Safety and Effectiveness in Children with Hypochondroplasia Until Adult Height is Reached

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Vosoritide
  • Sponsor:Biomarin Pharmaceutical Inc.

Fabry's disease

Recruiting

Title: Evaluating low-dose prednisone with standard therapy to improve heart function in patients with cardiac manifestations of Fabry disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Medical University Of Lodz

PIK3CA related overgrowth spectrum

Recruiting

Study of alpelisib in children and adults with PIK3CA-Related Overgrowth Spectrum (PROS)

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Metabolism and nutrition disorders trials.

Semaglutide77 clinical trialsSodium Chloride25 clinical trialsDapagliflozin23 clinical trialsTirzepatide17 clinical trialsEmpagliflozin16 clinical trialsCagrilintide15 clinical trialsPlacebo15 clinical trialsColecalciferol14 clinical trialsMetformin12 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.